Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Mijntje B, Vastbinder"'
Autor:
Stefan A. J. Buck, C. Louwrens Braal, Maaike M. Hofman, Esther Oomen-de Hoop, Peter de Bruijn, Inge M. Ghobadi Moghaddam-Helmantel, Koen G. A. M. Hussaarts, Mijntje B. Vastbinder, Quirine C. van Rossum-Schornagel, Ron H. N. van Schaik, Agnes Jager, Stijn L. W. Koolen, Ron H. J. Mathijssen
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Introduction: In breast cancer patients treated with the anti-estrogen tamoxifen, low concentrations of the active metabolite endoxifen are associated with more disease recurrence. We hypothesized that we could increase endoxifen concentrations by in
Externí odkaz:
https://doaj.org/article/258552e485654475a839962a4fd6a115
Autor:
Martine F Thijs-Visser, Mijntje B. Vastbinder, Liesbeth E. M. Struik, Hanneke J. M. Zuetenhorst, Justin D. Westenberg, C. Louwrens Braal, Koen M. W. T. Lommen, Ron H.J. Mathijssen, Robbert J. van Alphen, Stijn L.W. Koolen, Agnes Jager, Esther Oomen-de Hoop, Peter de Bruijn, Quirine C. van Rossum-Schornagel
Publikováno v:
Clinical Pharmacokinetics, 61(4), 527-537. Adis
Background: Endoxifen is the most important active metabolite of tamoxifen. Several retrospective studies have suggested a minimal or threshold endoxifen systemic concentration of 14–16 nM is required for a lower recurrence rate. The aim of this st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2284dea60a5044e1d335b11be933342
https://pure.eur.nl/en/publications/b67beed5-f844-4074-a150-898c7b3e6de5
https://pure.eur.nl/en/publications/b67beed5-f844-4074-a150-898c7b3e6de5
Autor:
C Louwrens, Braal, Agnes, Jager, Esther Oomen-de, Hoop, Justin D, Westenberg, Koen M W T, Lommen, Peter, de Bruijn, Mijntje B, Vastbinder, Quirine C, van Rossum-Schornagel, Martine F, Thijs-Visser, Robbert J, van Alphen, Liesbeth E M, Struik, Hanneke J M, Zuetenhorst, Ron H J, Mathijssen, Stijn L W, Koolen
Publikováno v:
Clinical pharmacokinetics. 61(4)
Endoxifen is the most important active metabolite of tamoxifen. Several retrospective studies have suggested a minimal or threshold endoxifen systemic concentration of 14-16 nM is required for a lower recurrence rate. The aim of this study was to inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cc5759601dbbcfda1b6f119837d89c71
https://pubmed.ncbi.nlm.nih.gov/34786650
https://pubmed.ncbi.nlm.nih.gov/34786650
Autor:
C. Louwrens Braal, Stefan A.J. Buck, Roelof W F van Leeuwen, Monique E. M. M. Bos, Daniëlle Mathijssen van Stein, Teun van Gelder, Martine F Thijs-Visser, Esther Oomen-de Hoop, Peter de Bruijn, Koen G A M Hussaarts, Agnes Jager, Ron H.J. Mathijssen, Mijntje B. Vastbinder, Stijn L.W. Koolen, Lieke Seuren, Hanneke J. M. Zuetenhorst
Publikováno v:
Breast Cancer Research and Treatment
Breast Cancer Res Treat
Breast Cancer Research and Treatment, 184(1), 107-113. SPRINGER
Breast Cancer Research and Treatment, 184(1), 107-113. Springer New York
Breast Cancer Res Treat
Breast Cancer Research and Treatment, 184(1), 107-113. SPRINGER
Breast Cancer Research and Treatment, 184(1), 107-113. Springer New York
Background Many cancer patients use additional herbs or supplements in combination with their anti-cancer therapy. Green tea—active ingredient epigallocatechin-3-gallate (EGCG)—is one of the most commonly used dietary supplements among breast can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::370a440a75969aa38d2f154a6b5408df
https://doi.org/10.1007/s10549-020-05829-6
https://doi.org/10.1007/s10549-020-05829-6
Autor:
Mijntje B. Vastbinder, Agnes Jager, Roelof W F van Leeuwen, Leonie J van Harten, Esther Oomen-de Hoop, Leontine E.A. Spierings, Ron H.J. Mathijssen, Teun van Gelder, Koen G A M Hussaarts, Stan Berghuis, Daan P. Hurkmans, Robbert J. van Alphen, Ron H.N. van Schaik, Quirine C. van Rossum-Schornagel
Publikováno v:
Cancers
Volume 11
Issue 3
Cancers, 11(3):403. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, Vol 11, Iss 3, p 403 (2019)
Volume 11
Issue 3
Cancers, 11(3):403. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, Vol 11, Iss 3, p 403 (2019)
Tamoxifen is a prodrug that is primarily metabolized into the pharmacologically active metabolite endoxifen and eventually into inactive metabolites. The herb curcumin may increase endoxifen exposure by affecting phase II metabolism. We compared endo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5a6300c082c1dba95fe98d7a4423dc4
Autor:
Mijntje B. Vastbinder, Bernadette A M Heemskerk-Gerritsen, Mark van Barele, Yvonne V. Louwers, Maartje J. Hooning, John W.M. Martens, Agnes Jager
Publikováno v:
Cancers
Cancers, Vol 13, Iss 2506, p 2506 (2021)
Cancers, Vol 13, Iss 2506, p 2506 (2021)
Simple Summary Young women treated for breast cancer may experience early menopause, which can negatively impact quality of life. The usual treatment for early menopause is hormone replacement. For hormone-sensitive breast cancers, however, hormones
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab678ff67c1c838452156bf2a5bf5888
https://doi.org/10.3390/cancers13112506
https://doi.org/10.3390/cancers13112506
Autor:
Hanneke J. M. Zuetenhorst, Roelof W F van Leeuwen, Esther Oomen‑deHoop, Koen G A M Hussaarts, Monique E. M. M. Bos, Peter de Bruijn, Stefan A.J. Buck, Daniëlle Mathijssen van Stein, Teun van Gelder, Mijntje B. Vastbinder, Lieke Seuren, Ron H.J. Mathijssen, Martine F. Thijs‑Visser, Agnes Jager, Stijn L.W. Koolen, C. Louwrens Braal
Publikováno v:
Breast Cancer Research and Treatment. 185:889-889
Unfortunately, the original version of the article was published with incorrect copyright as “© Springer Science + Business Media, LLC, part of Springer Nature 2020”.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d6dd71c31fa135efcec2b3456514ab4
https://doi.org/10.1007/s10549-020-05979-7
https://doi.org/10.1007/s10549-020-05979-7
Autor:
T. van Gelder, L. Braal, Martine F Thijs-Visser, M.M.E.M. Bos, Lieke Seuren, R. van Leeuwen, Stefan A.J. Buck, J.M. Zuetenhorst, D. Mathijssen-van Stein, Stijn L.W. Koolen, E. Oomen-de Hoop, P. de Bruijn, Mijntje B. Vastbinder, Ron H.J. Mathijssen, Koen G A M Hussaarts
Publikováno v:
Annals of Oncology. 31:S324
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4abfecd92b7c3139f11ee98ef64d2040
https://doi.org/10.1016/j.annonc.2020.08.327
https://doi.org/10.1016/j.annonc.2020.08.327
Autor:
Daan P. Hurkmans, Quirine C. van Rossum, Agnes Jager, Esther Oomen-de Hoop, Robbert J. van Alphen, Gerardus Hussaarts, Mijntje B. Vastbinder, Leonie J van Harten, Roelof W F van Leeuwen, Stan Berghuis, Ron H.N. van Schaik, Leontine E.A. Spierings, Teun van Gelder, Ron H.J. Mathijssen
Publikováno v:
Journal of Clinical Oncology. 36:2572-2572
2572Background: Tamoxifen is extensively used as endocrine therapy for breast cancer. It is a prodrug that is primarily metabolized by CYP2D6 and CYP3A4, particular into endoxifen. In daily practic...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67894eebc028770672ac11e1a907dcac
https://doi.org/10.1200/jco.2018.36.15_suppl.2572
https://doi.org/10.1200/jco.2018.36.15_suppl.2572